Assessing the evidence on remdesivir.

Trøseid, Marius; Hites, Maya; Barratt-Due, Andreas; Ader, Florence; Yazdanpanah, Yazdan

Trøseid, Marius; Hites, Maya; Barratt-Due, Andreas; Ader, Florence; Yazdanpanah, Yazdan.

Trøseid M; Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital, 0424 Oslo, Norway. Electronic address: marius.troseid@medisin.uio.no.
Hites M; Cliniques Universitaires de Bruxelles-Hôpital Érasme, Université Libre de Bruxelles, Clinique des Maladies Infectieuses, Brussels.
Barratt-Due A; Division of Critical Care and Emergencies, Oslo University Hospital, 0424 Oslo, Norway.
Ader F; Département des Maladies Infectieuses et Tropicales, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France.
Yazdanpanah Y; Université de Paris, IAME, INSERM, Paris, France.

Lancet Infect Dis ; 21(12): 1630-1631, 2021 12.

Article in English | MEDLINE | ID: covidwho-2170696

Subject(s)

Adenosine Monophosphate/analogs & derivatives; Alanine/analogs & derivatives; Antiviral Agents/therapeutic use; Adenosine Monophosphate/therapeutic use; Alanine/therapeutic use; Humans; Randomized Controlled Trials as Topic; SARS-CoV-2; Treatment Outcome; COVID-19 Drug Treatment

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Adenosine Monophosphate / Alanine Type of study: Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Lancet Infect Dis Journal subject: Communicable Diseases Year: 2021 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google